- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05863351
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To compare overall survival (OS) between patients receiving SAbR + systemic therapy (SABR+ST) versus systemic therapy (ST) only.
II. To compare average adverse event (AE) score between SAbR+ST arm and ST only arm.
SECONDARY OBJECTIVES:
I. To compare global health status / quality of life (QOL) between patients receiving SAbR+ST versus ST only.
II. To compare progression-free survival (PFS) between the arms.
EXPLORATORY OBJECTIVES:
I. To estimate PFS on first line systemic therapy (PFS-SST) in the SAbR+ST arm and compare with first line systemic therapy PFS of the ST arm.
II. To explore local control from SAbR by looking at the amount of local failures after SAbR in the SAbR+ST arm.
III. To assess the cost-effectiveness between the arms in terms of cost per unit gain in quality-of-life years.
QOL OBJECTIVES:
I. To compare global health status / quality of life (QOL) between patients receiving SabR+ST versus ST only using the National Comprehensive Cancer Network (NCCN) / Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index -19 item (NFKSI-19).
II. To compare quality-adjusted survival between patients randomized to receive SabR+ST vs ST alone using European Quality of Life (EUROQOL) 5-dimension, 5-level (EQ-5D-5L) at 3, 6, 9, 12, 18, and 24 months.
III. To compare global health status / QOL of the NFKSI-19 at all of the 3, 6, 9, 12, 18, and 24 month time points between patients randomized to receive SabR+ST versus ST alone.
IV. To compare scale scores of the NFKSI-19 (disease-related symptoms - physical disease-related symptoms - emotional, treatment side effects, and function & well-being) at 3, 6, 9, 12, 18, 24 months between patients randomized to receive SabR+ST versus ST alone.
V. To compare time to global quality of life deterioration between patients randomized to receive SabR+ST versus ST alone using NFKSI-19.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive standard of care systemic therapy on study.
ARM II: Patients undergo repeated SAbR until progression and then receive standard of care systemic therapy on study.
Patients in both arms undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham Cancer Center
-
Principal Investigator:
- Andrew M. McDonald
-
Contact:
- Site Public Contact
- Phone Number: 205-934-0220
- Email: tmyrick@uab.edu
-
-
Illinois
-
Bloomington, Illinois, United States, 61704
- Recruiting
- Illinois CancerCare-Bloomington
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Bloomington, Illinois, United States, 61701
- Recruiting
- Saint Joseph Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Canton, Illinois, United States, 61520
- Recruiting
- Illinois CancerCare-Canton
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Carthage, Illinois, United States, 62321
- Recruiting
- Illinois CancerCare-Carthage
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Centralia, Illinois, United States, 62801
- Recruiting
- Centralia Oncology Clinic
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Site Public Contact
- Phone Number: 312-695-1301
- Email: cancer@northwestern.edu
-
Principal Investigator:
- Sean Sachdev
-
Danville, Illinois, United States, 61832
- Recruiting
- Carle at The Riverfront
-
Principal Investigator:
- Daniel H. Barnett
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
DeKalb, Illinois, United States, 60115
- Recruiting
- Northwestern Medicine Cancer Center Kishwaukee
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Principal Investigator:
- Sean Sachdev
-
Decatur, Illinois, United States, 62526
- Recruiting
- Cancer Care Specialists of Illinois - Decatur
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, United States, 62526
- Recruiting
- Decatur Memorial Hospital
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, United States, 62401
- Recruiting
- Carle Physician Group-Effingham
-
Principal Investigator:
- Daniel H. Barnett
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Effingham, Illinois, United States, 62401
- Recruiting
- Crossroads Cancer Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Eureka, Illinois, United States, 61530
- Recruiting
- Illinois CancerCare-Eureka
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Galesburg, Illinois, United States, 61401
- Recruiting
- Illinois CancerCare-Galesburg
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Geneva, Illinois, United States, 60134
- Recruiting
- Northwestern Medicine Cancer Center Delnor
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Principal Investigator:
- Sean Sachdev
-
Kewanee, Illinois, United States, 61443
- Recruiting
- Illinois CancerCare-Kewanee Clinic
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Macomb, Illinois, United States, 61455
- Recruiting
- Illinois CancerCare-Macomb
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Mattoon, Illinois, United States, 61938
- Recruiting
- Carle Physician Group-Mattoon/Charleston
-
Principal Investigator:
- Daniel H. Barnett
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
O'Fallon, Illinois, United States, 62269
- Suspended
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, United States, 61350
- Recruiting
- Illinois CancerCare-Ottawa Clinic
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Pekin, Illinois, United States, 61554
- Recruiting
- Illinois CancerCare-Pekin
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peoria, Illinois, United States, 61615
- Recruiting
- Illinois CancerCare-Peoria
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peoria, Illinois, United States, 61615
- Recruiting
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peoria, Illinois, United States, 61637
- Recruiting
- OSF Saint Francis Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Peru, Illinois, United States, 61354
- Recruiting
- Illinois CancerCare-Peru
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Princeton, Illinois, United States, 61356
- Recruiting
- Illinois CancerCare-Princeton
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
Springfield, Illinois, United States, 62702
- Recruiting
- Southern Illinois University School of Medicine
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-545-7929
-
Springfield, Illinois, United States, 62702
- Recruiting
- Springfield Clinic
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 800-444-7541
-
Springfield, Illinois, United States, 62781
- Recruiting
- Memorial Medical Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-528-7541
- Email: pallante.beth@mhsil.com
-
Urbana, Illinois, United States, 61801
- Recruiting
- Carle Cancer Center
-
Principal Investigator:
- Daniel H. Barnett
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Warrenville, Illinois, United States, 60555
- Recruiting
- Northwestern Medicine Cancer Center Warrenville
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Principal Investigator:
- Sean Sachdev
-
Washington, Illinois, United States, 61571
- Recruiting
- Illinois CancerCare - Washington
-
Contact:
- Site Public Contact
- Phone Number: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Principal Investigator:
- Bryan A. Faller
-
-
Iowa
-
Ames, Iowa, United States, 50010
- Recruiting
- Mary Greeley Medical Center
-
Principal Investigator:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Phone Number: 515-956-4132
-
Ames, Iowa, United States, 50010
- Recruiting
- McFarland Clinic - Ames
-
Principal Investigator:
- Joseph J. Merchant
-
Contact:
- Site Public Contact
- Phone Number: 515-239-4734
- Email: ksoder@mcfarlandclinic.com
-
Ankeny, Iowa, United States, 50023
- Recruiting
- Mission Cancer and Blood - Ankeny
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-282-2921
-
Cedar Rapids, Iowa, United States, 52403
- Recruiting
- Mercy Hospital
-
Contact:
- Site Public Contact
- Phone Number: 319-365-4673
-
Principal Investigator:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, United States, 52403
- Recruiting
- Oncology Associates at Mercy Medical Center
-
Principal Investigator:
- Deborah W. Wilbur
-
Contact:
- Site Public Contact
- Phone Number: 319-363-2690
-
Clive, Iowa, United States, 50325
- Recruiting
- Medical Oncology and Hematology Associates-West Des Moines
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Richard L. Deming
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Medical Oncology and Hematology Associates-Des Moines
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Des Moines, Iowa, United States, 50314
- Recruiting
- Mission Cancer and Blood - Laurel
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Richard L. Deming
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Iowa Methodist Medical Center
-
Principal Investigator:
- Joshua Lukenbill
-
Contact:
- Site Public Contact
- Phone Number: 515-241-6727
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Recruiting
- University of Kansas Clinical Research Center
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Olathe, Kansas, United States, 66061
- Recruiting
- Olathe Health Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 913-355-8000
- Email: Jeni.wakefield@olathehealth.org
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Overland Park, Kansas, United States, 66211
- Recruiting
- University of Kansas Hospital-Indian Creek Campus
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Overland Park, Kansas, United States, 66210
- Recruiting
- University of Kansas Cancer Center-Overland Park
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Salina, Kansas, United States, 67401
- Recruiting
- Salina Regional Health Center
-
Contact:
- Site Public Contact
- Phone Number: 785-452-7038
- Email: mleepers@srhc.com
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Topeka, Kansas, United States, 66606
- Recruiting
- University of Kansas Health System Saint Francis Campus
-
Contact:
- Site Public Contact
- Phone Number: 785-295-8000
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Westwood, Kansas, United States, 66205
- Recruiting
- University of Kansas Hospital-Westwood Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Recruiting
- Saint Joseph Mercy Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Brighton, Michigan, United States, 48114
- Recruiting
- Saint Joseph Mercy Brighton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Brighton, Michigan, United States, 48114
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Canton, Michigan, United States, 48188
- Recruiting
- Saint Joseph Mercy Canton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Canton, Michigan, United States, 48188
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Chelsea, Michigan, United States, 48118
- Recruiting
- Saint Joseph Mercy Chelsea
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Chelsea, Michigan, United States, 48118
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Lansing, Michigan, United States, 48912
- Recruiting
- Sparrow Hospital
-
Contact:
- Site Public Contact
- Phone Number: 517-364-9400
-
Principal Investigator:
- Samir Narayan
-
Livonia, Michigan, United States, 48154
- Recruiting
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
Ypsilanti, Michigan, United States, 48197
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Samir Narayan
-
-
Missouri
-
Cape Girardeau, Missouri, United States, 63703
- Recruiting
- Saint Francis Medical Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 573-334-2230
- Email: sfmc@sfmc.net
-
Kansas City, Missouri, United States, 64154
- Recruiting
- University of Kansas Cancer Center - North
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Lee's Summit, Missouri, United States, 64064
- Recruiting
- University of Kansas Cancer Center - Lee's Summit
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
North Kansas City, Missouri, United States, 64116
- Recruiting
- University of Kansas Cancer Center at North Kansas City Hospital
-
Contact:
- Site Public Contact
- Phone Number: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Principal Investigator:
- Elizabeth M. Wulff-Burchfield
-
Saint Louis, Missouri, United States, 63141
- Recruiting
- Mercy Hospital Saint Louis
-
Principal Investigator:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Phone Number: 314-251-7066
-
Saint Louis, Missouri, United States, 63128
- Recruiting
- Mercy Hospital South
-
Principal Investigator:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Phone Number: 314-525-6042
- Email: Danielle.Werle@mercy.net
-
Springfield, Missouri, United States, 65804
- Recruiting
- Mercy Hospital Springfield
-
Principal Investigator:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Phone Number: 417-269-4520
-
-
New York
-
Lake Success, New York, United States, 11042
- Recruiting
- Northwell Health/Center for Advanced Medicine
-
Principal Investigator:
- Louis Potters
-
Contact:
- Site Public Contact
- Phone Number: 516-734-8896
-
New York, New York, United States, 10021
- Recruiting
- Lenox Hill Hospital
-
Principal Investigator:
- Louis Potters
-
Contact:
- Site Public Contact
- Phone Number: 516-734-8896
-
New York, New York, United States, 10065
- Recruiting
- Manhattan Eye Ear and Throat Hospital
-
Principal Investigator:
- Louis Potters
-
Contact:
- Site Public Contact
- Phone Number: 212-434-4460
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Recruiting
- Sanford Bismarck Medical Center
-
Principal Investigator:
- Daniel Almquist
-
Contact:
- Site Public Contact
- Phone Number: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, United States, 58122
- Recruiting
- Sanford Broadway Medical Center
-
Principal Investigator:
- Daniel Almquist
-
Contact:
- Site Public Contact
- Phone Number: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, United States, 58122
- Recruiting
- Sanford Roger Maris Cancer Center
-
Principal Investigator:
- Daniel Almquist
-
Contact:
- Site Public Contact
- Phone Number: 701-234-6161
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Phone Number: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Principal Investigator:
- Tyler Gunter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Recruiting
- ECOG-ACRIN Cancer Research Group
-
Contact:
- Raquibul Hannan
- Email: raquibul.hannan@utsouthwestern.edu
-
Principal Investigator:
- Raquibul Hannan
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57104
- Recruiting
- Sanford Cancer Center Oncology Clinic
-
Principal Investigator:
- Daniel Almquist
-
Contact:
- Site Public Contact
- Phone Number: 605-312-3320
- Email: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, United States, 57117-5134
- Recruiting
- Sanford USD Medical Center - Sioux Falls
-
Principal Investigator:
- Daniel Almquist
-
Contact:
- Site Public Contact
- Phone Number: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Principal Investigator:
- Qian Qin
-
Dallas, Texas, United States, 75237
- Recruiting
- UT Southwestern Simmons Cancer Center - RedBird
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Principal Investigator:
- Qian Qin
-
Fort Worth, Texas, United States, 76104
- Recruiting
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Principal Investigator:
- Qian Qin
-
Richardson, Texas, United States, 75080
- Recruiting
- UT Southwestern Clinical Center at Richardson/Plano
-
Contact:
- Site Public Contact
- Phone Number: 972-669-7044
- Email: Suzanne.cole@utsouthwestern.edu
-
Principal Investigator:
- Qian Qin
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University/Massey Cancer Center
-
Contact:
- Site Public Contact
- Email: CTOclinops@vcu.edu
-
Principal Investigator:
- John Melson
-
Richmond, Virginia, United States, 23235
- Recruiting
- VCU Massey Cancer Center at Stony Point
-
Contact:
- Site Public Contact
- Email: CTOclinops@vcu.edu
-
Principal Investigator:
- John Melson
-
-
Wisconsin
-
Eau Claire, Wisconsin, United States, 54701
- Recruiting
- Marshfield Medical Center-EC Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Marshfield, Wisconsin, United States, 54449
- Recruiting
- Marshfield Medical Center-Marshfield
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Minocqua, Wisconsin, United States, 54548
- Recruiting
- Marshfield Clinic-Minocqua Center
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Rice Lake, Wisconsin, United States, 54868
- Recruiting
- Marshfield Medical Center-Rice Lake
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Stevens Point, Wisconsin, United States, 54482
- Recruiting
- Marshfield Medical Center-River Region at Stevens Point
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
Weston, Wisconsin, United States, 54476
- Recruiting
- Marshfield Medical Center - Weston
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Anderson A. Bauer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be >= 18 years of age
- Patient must have a pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma (RCC) prior to randomization
- Patient may have any RCC histology except a histology that has a sarcomatoid component
- Patient must have primary site addressed by local therapy. If the primary RCC is intact, the patient must undergo local treatment to the primary before randomization
- Patient must have favorable or intermediate International Metastatic RCC Database Consortium (IMDC) risk (0-2) at the time of randomization
- Patient must have a total of between 2 and 5 metastatic lesions, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria with imaging obtained within 45 days prior to randomization
- Patient must have a documentation from a radiation oncologist confirming that all sites are amenable to SAbR
- Patient may have received prior therapy in the adjuvant setting as long as potential trial participants have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy
A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
- Has achieved menarche at some point
- Has not undergone a hysterectomy or bilateral oophorectomy
- Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
- Patient must have a Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Patients must have adequate organ and bone marrow function as per the recommended guidelines and the respective Food and Drug Administration [FDA] package insert required for the systemic therapy chosen by the treating oncologist. We recognize that patients may have varying levels of renal and liver function that will impact which systemic therapy is appropriate for the patient. We do not require all patients to have specific baseline laboratory thresholds but do ask the treating oncologist to attest that the patient has adequate organ and bone marrow function to safely receive one of the first line systemic therapies listed in the protocol as a standard of care treatment option
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial. Testing for HIV is not required for entry onto the study
- For patients with history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. If no previous history, testing for HBV is not required for entry onto the study
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. If no previous history, testing for HCV is not required for entry onto the study
In order to participate in the QOL portion of the protocol, the patient must speak one of the languages in which the NFKSI-19 and EQ-5D-5L is available
- NOTE: Sites cannot translate the associated QOL forms
Exclusion Criteria:
- Patient must not have brain metastases
- Patient must not have metastasis involving the following locations: ultra-central (within 2cm of carina) lung, invading gastrointestinal tract (such as esophagus, stomach, intestines, colon, rectum), skin, and scalp
- Patient must not have received any prior systemic therapy (except for adjuvant setting) for metastatic RCC
- Active autoimmune disease requiring ongoing therapy including systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications daily. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
- History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies
- Active tuberculosis (purified protein derivative [PPD] response without active TB is allowed)
- Uncontrolled hypertension (systolic blood pressure [BP] > 190mmHg or diastolic BP > 110mmHg)
- Major surgery within 30 days prior to randomization
- Any serious (requiring hospital stay or long term rehab) non-healing wound, ulcer, or bone fracture within 30 days prior to randomization
- Any arterial thrombotic (ST elevation myocardial infarction [STEMI], non-STEMI [NSTEMI], cerebrovascular accident [CVA], etc.) events within 180 days prior to randomization
- Moderate or severe hepatic impairment (child-Pugh B or C)
- Untreated pulmonary embolism (PE) or deep-vein thrombosis (DVT) is not allowed. Treated PE or DVT is allowed > 30 days from diagnosis and when not resulting in respiratory impairment
- Unstable cardiac arrhythmia within 180 days prior to randomization
- History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel obstruction, or gastric outlet obstruction within 180 days prior to randomization
- History of or active inflammatory bowel disease
- Malabsorption syndrome within 30 days prior to randomization
- Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used
- Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after the last dose of protocol treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (usual care)
Patients receive standard of care systemic therapy on study.
Patients undergo CT or MRI throughout the trial.
|
Ancillary studies
Undergo MRI
Other Names:
Undergo CT
Other Names:
Given standard of care systemic therapy
|
Experimental: Arm II (SAbR, usual care)
Patients undergo repeated SAbR until progression and then receive standard of care systemic therapy on study.
Patients undergo CT or MRI throughout the trial.
|
Ancillary studies
Undergo MRI
Other Names:
Undergo CT
Other Names:
Given standard of care systemic therapy
Undergo SAbR
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: From randomization to death from any cause, assessed up to 10 years
|
The repeated confidence interval method will be utilized.
At each scheduled interim analysis, a one-sided 95% repeated confidence interval of hazard ratio (stereotactic ablative radiotherapy [SAbR] + standard therapy [ST] / ST) will be computed, using the partial likelihood estimate, to test non-inferiority in OS for SAbR+ST arm.
|
From randomization to death from any cause, assessed up to 10 years
|
Incidence of adverse events (AEs)
Time Frame: From randomization up to 6 months
|
All patients who receive treatment, regardless of eligibility, will be evaluated for AE/toxicity.
AE score will be calculated in 3-month intervals starting from randomization.
To calculate the AE score for a 3-month interval, for each patient, the AE sub-score for each Common Terminology Criteria for Adverse Events (CTCAE) categories (there are 26 AE categories listed in CTCAE version 5) will be aggregated based on the highest grade of AE experienced in each CTCAE category.
|
From randomization up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From randomization to progression of disease, assessed up to 10 years
|
Patients randomized to SAbR will need to first progress on SAbR, then progress on systemic therapy to be counted as an event for progression.
Progression on SAbR is when SAbR (sequential SAbR) is unable to control the disease by meeting one of the two criteria: > 6 metastases in total requiring SAbR (no matter how many metastases a patient was randomized with), or one or more progressing lesions not amenable to SAbR (> 5% risk of grade 3 toxicity by American Society for Therapeutic Radiology and Oncology definition).
This endpoint will be compared between the two arms using stratified log-rank test, at one-sided 0.025 significance level.
|
From randomization to progression of disease, assessed up to 10 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS-start of systemic therapy (SST)
Time Frame: From the start of SST to progression or death, assessed up to 10 years
|
Compare the PFS from the start of systemic therapy (instead of from the time of randomization) of Arm A (after PFS-SAbR) with PFS of upfront systemic therapy in Arm B. This endpoint will be descriptive and will only be explored in arm A. Will explore local control that SAbR provides, by looking at local failures after SAbR in SAbR+ST arm only.
Local failure is defined as > 30% increase in the longest diameter of SAbR-treated lesion, more than 6 months post SAbR treatment.
|
From the start of SST to progression or death, assessed up to 10 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Raquibul Hannan, ECOG-ACRIN Cancer Research Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
Other Study ID Numbers
- EA8211 (Other Identifier: CTEP)
- U10CA180820 (U.S. NIH Grant/Contract)
- NCI-2023-02060 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
-
iOMEDICO AGNovartis PharmaceuticalsCompletedCarcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell CarcinomaGermany
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedMetastatic Renal Cell Carcinoma | Metastatic Kidney CancerFrance
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingStage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Bladder Adenocarcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Bladder... and other conditionsUnited States, Puerto Rico
-
Duke UniversityCompletedMetastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
Prometheus LaboratoriesCompletedMetastatic Renal Cell Carcinoma | Metastatic MelanomaUnited States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation